Torrent Pharmaceuticals Ltd share Price Today

Incorporated in 1959, Torrent remains a key play in branded generics (~60% of sales) with strong India franchise and growing exports traction.

• Revenues – India including CRAMs (59.8%), Brazil (8.3%), US (11.3%) and Germany (10.4%)
• Torrent is the eighth largest domestic player and is ranked in top 10 for CVS, CNS, V&M, GI and anti-diabetes therapies in India

Growth in revenues boosted by branded generic markets i.e. India and Brazil.

• Revenues grew 18.3% YoY to ₹ 2491 crore
• EBITDA margins expanded ~361 bps YoY to 29.1%. EBITDA increased 35.1% to ₹ 724 crore
• PAT increased 13.73% YoY to ₹ 283 crore

Torrent Pharmaceuticals announced Q3FY24 results:

Financial Performance for Q3FY24:

• Revenue: Rs 2,732 crore, indicating a 10% increase.
• Gross Margin: 75%, maintaining a stable position in the market.
• Operational EBITDA: Rs 869 crore, experiencing a 20% growth.
• Exceptional Items: Gained net proceeds of Rs 88 crore from the sale of a US facility.
• Net Profit After Tax (PAT): Rs 443 crore, marking a significant 52% surge.
• Research & Development (R&D) Spend: Rs 127 crore, reaffirming the company's commitment to innovation.
• Debt Equity Ratio: A ratio of 0.53, indicating a moderate level of debt in comparison to equity.
• Debt Service Coverage Ratio: At 2.21, suggesting the company's ability to service its debt is well-managed.
• Interest Service Coverage Ratio: Standing at 9.08, showing a strong ability to meet interest expenses.
• Net Profit Margin: The net profit margin stood at 16%, representing the profitability from the revenue earned.

Country-wise Performance for Q3FY24:

• India: Revenues reached Rs 1,415 crore, up by 12%, outperforming the market in focus therapies.
• Brazil: Reported revenues of Rs 312 crore, growing by 26%, with constant currency revenues up by 17%.
• Germany: Achieved revenues of Rs 270 crore, increasing by 12%, with constant currency revenues rising by 6% due to tender wins.
• United States: US business revenues saw a slight decrease of 6% to Rs 274 crore, with constant currency revenues down by 7%, affected by a lack of new product launches.

Result PDF